Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EBS Emergent Biosolutions	$6.27 -0.6%	$5.83	$4.02 ▼ $15.10	$342.49M	2.1	1.78 million shs	2.48 million shs
RIGL Rigel Pharmaceuticals	$18.93 -2.2%	$19.28	$7.48 ▼ $29.82	$346.01M	1.29	221,678 shs	304,828 shs
SGMO Sangamo Therapeutics	$0.46 -6.8%	$0.59	$0.30 ▼ $3.18	$114.51M	1.19	8.91 million shs	4.71 million shs
VSTM Verastem	$4.93 -5.0%	$6.70	$2.10 ▼ $9.10	$285.19M	0.85	1.18 million shs	7.28 million shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EBS Emergent Biosolutions	-0.55%	+0.11%	-2.61%	+10.13%	+3.50%
RIGL Rigel Pharmaceuticals	-2.22%	-7.75%	-9.60%	-6.29%	+109.70%
SGMO Sangamo Therapeutics	-6.84%	-6.82%	-8.50%	-47.21%	+8.62%
VSTM Verastem	-5.01%	-11.96%	-35.22%	-25.86%	+50.76%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EBS Emergent Biosolutions	4.4235 of 5 stars	3.5	2.0	4.6	2.6	2.5	1.3
RIGL Rigel Pharmaceuticals	3.7012 of 5 stars	3.2	2.0	0.0	3.5	1.7	3.1
SGMO Sangamo Therapeutics	1.3384 of 5 stars	3.3	2.0	0.0	0.0	0.8	0.6
VSTM Verastem	2.5242 of 5 stars	3.5	2.0	0.0	2.0	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EBS Emergent Biosolutions	3.00	Buy	$14.33	128.53% Upside
RIGL Rigel Pharmaceuticals	2.40	Hold	$36.40	92.29% Upside
SGMO Sangamo Therapeutics	2.67	Moderate Buy	$4.50	883.61% Upside
VSTM Verastem	3.00	Buy	$13.63	176.37% Upside

Current Analyst Ratings Breakdown

Latest SGMO, RIGL, EBS, and VSTM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/14/2025	SGMO Sangamo Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$9.00 ➝ $5.00
5/9/2025	VSTM Verastem	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $14.00
5/7/2025	RIGL Rigel Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$20.00 ➝ $23.00
4/10/2025	VSTM Verastem	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
4/9/2025	VSTM Verastem	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$9.00 ➝ $8.00
4/7/2025	SGMO Sangamo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
4/1/2025	EBS Emergent Biosolutions	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
3/24/2025	VSTM Verastem	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $14.00
3/24/2025	VSTM Verastem	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $10.00
3/21/2025	EBS Emergent Biosolutions	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
3/21/2025	VSTM Verastem	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$16.00 ➝ $14.00

(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EBS Emergent Biosolutions	$930.30M	0.37	$1.91 per share	3.28	$8.91 per share	0.70
RIGL Rigel Pharmaceuticals	$179.28M	1.89	$1.06 per share	17.94	$0.19 per share	99.63
SGMO Sangamo Therapeutics	$57.80M	1.85	N/A	N/A	$0.11 per share	4.16
VSTM Verastem	$10K	27,090.35	N/A	N/A	($0.65) per share	-7.58

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EBS Emergent Biosolutions	-$190.60M	-$2.71	N/A	3.03	N/A	-13.63%	-0.52%	-0.17%	8/5/2025 (Estimated)
RIGL Rigel Pharmaceuticals	$17.49M	$2.07	9.14	18.03	N/A	18.31%	-655.26%	24.47%	8/5/2025 (Estimated)
SGMO Sangamo Therapeutics	-$97.94M	-$0.39	N/A	N/A	N/A	-124.61%	-345.98%	-79.86%	8/5/2025 (Estimated)
VSTM Verastem	-$130.64M	-$3.20	N/A	N/A	N/A	N/A	-2,003.62%	-127.97%	8/6/2025 (Estimated)

Latest SGMO, RIGL, EBS, and VSTM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	VSTM Verastem	-$0.72	-$0.96	-$0.24	-$0.96	$0.10 million	N/A
5/12/2025	Q1 2025	SGMO Sangamo Therapeutics	-$0.11	-$0.14	-$0.03	-$0.14	$7.90 million	$6.44 million
5/7/2025	Q1 2025	EBS Emergent Biosolutions	$0.49	$0.71	+$0.22	$1.19	$218.50 million	$222.20 million
5/6/2025	Q1 2025	RIGL Rigel Pharmaceuticals	$0.14	$0.63	+$0.49	$0.63	$43.87 million	$53.33 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EBS Emergent Biosolutions	N/A	N/A	N/A	N/A	N/A
RIGL Rigel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SGMO Sangamo Therapeutics	N/A	N/A	N/A	N/A	N/A
VSTM Verastem	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EBS Emergent Biosolutions	1.20	6.32	3.51
RIGL Rigel Pharmaceuticals	2.42	2.20	2.13
SGMO Sangamo Therapeutics	N/A	0.76	0.76
VSTM Verastem	2.77	3.50	3.50

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EBS Emergent Biosolutions	78.40%
RIGL Rigel Pharmaceuticals	66.23%
SGMO Sangamo Therapeutics	56.93%
VSTM Verastem	88.37%

Insider Ownership

Company	Insider Ownership
EBS Emergent Biosolutions	1.20%
RIGL Rigel Pharmaceuticals	9.48%
SGMO Sangamo Therapeutics	4.10%
VSTM Verastem	2.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EBS Emergent Biosolutions	2,420	54.28 million	53.63 million	Optionable
RIGL Rigel Pharmaceuticals	160	17.87 million	16.18 million	Optionable
SGMO Sangamo Therapeutics	480	233.17 million	223.61 million	Optionable
VSTM Verastem	50	54.95 million	53.80 million	Optionable

SGMO, RIGL, EBS, and VSTM Headlines

Recent News About These Companies

Financial Contrast: Verastem (NASDAQ:VSTM) vs. Ensysce Biosciences (NASDAQ:ENSC)

June 16, 2025 | americanbankingnews.com

Verastem’s SWOT analysis: biotech stock poised for growth amid challenges

June 15, 2025 | investing.com

Verastem reports promising cancer drug trial results

June 4, 2025 | investing.com

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor

June 4, 2025 | businesswire.com

Verastem’s Promising Clinical Advances and Strategic Developments Justify Buy Rating

June 3, 2025 | tipranks.com

Verastem, Inc. (NASDAQ:VSTM) Receives Average Recommendation of "Buy" from Brokerages

June 3, 2025 | marketbeat.com

Verastem Announces Positive Data From Cancer Trial Conducted By Partner: Retail Turns Bullish

June 2, 2025 | msn.com

Verastem Announces Strategic Plans in Investor Webcast

June 2, 2025 | tipranks.com

What's Going On With Verastem Oncology Stock On Monday?

June 2, 2025 | benzinga.com

Verastem, Inc. (NASDAQ:VSTM) Short Interest Update

June 2, 2025 | marketbeat.com

Verastem Announces Promising Phase 1 Study Results

June 2, 2025 | tipranks.com

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor

June 2, 2025 | businesswire.com

Investors Buy Large Volume of Verastem Call Options (NASDAQ:VSTM)

May 31, 2025 | marketbeat.com

VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval

May 28, 2025 | zacks.com

Verastem Oncology to Present at the Jefferies Global Healthcare Conference

May 28, 2025 | businesswire.com

Northern Trust Corp Boosts Holdings in Verastem, Inc. (NASDAQ:VSTM)

May 28, 2025 | marketbeat.com

723,806 Shares in Verastem, Inc. (NASDAQ:VSTM) Bought by Woodline Partners LP

May 27, 2025 | marketbeat.com

BNP Paribas Financial Markets Makes New $387,000 Investment in Verastem, Inc. (NASDAQ:VSTM)

May 27, 2025 | marketbeat.com

Verastem’s SWOT analysis: biotech firm’s stock poised for growth amid challenges

May 23, 2025 | investing.com

Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline ...

May 23, 2025 | finance.yahoo.com

Verastem expands ambitions with strong pancreatic cancer data at ASCO

May 23, 2025 | thepharmaletter.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGMO, RIGL, EBS, and VSTM Company Descriptions

Emergent Biosolutions NYSE:EBS

$6.27 -0.04 (-0.60%)

Closing price 06/20/2025 03:59 PM Eastern

Extended Trading

$6.40 +0.13 (+2.04%)

As of 06/20/2025 06:51 PM Eastern

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Rigel Pharmaceuticals NASDAQ:RIGL

$18.93 -0.43 (-2.22%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$19.14 +0.21 (+1.11%)

As of 06/20/2025 07:51 PM Eastern

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

Sangamo Therapeutics NASDAQ:SGMO

$0.46 -0.03 (-6.84%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$0.47 +0.01 (+2.95%)

As of 06/20/2025 07:59 PM Eastern

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.

Verastem NASDAQ:VSTM

$4.93 -0.26 (-5.01%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$5.09 +0.16 (+3.33%)

As of 06/20/2025 07:55 PM Eastern

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time